Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0002005369-25-000012
Filing Date
2025-07-31
Accepted
2025-07-31 14:56:34
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16572
  Complete submission text file 0002005369-25-000012.txt   18289
Mailing Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022
Business Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 212-371-1717
Invus Global Management, LLC (Filed by) CIK: 0002005369 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 245 MAIN STREET CAMBRIDGE MA 02142
Business Address 245 MAIN STREET CAMBRIDGE MA 02142 617-785-8308
Bicara Therapeutics Inc. (Subject) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94620 | Film No.: 251171176
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)